Xi Chen | Preimplantation Genetic Testing | Best Researcher Award

Posted on by Pencis

Ms. Xi Chen | Preimplantation Genetic Testing | Best Researcher Award

Peking University Third Hospital | China

AUTHOR PROFILE

SCOPUS ID

🏥MS. XI CHEN: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Ms. Xi Chen embarked on her academic journey at Shandong University, where she earned a Bachelor’s degree in Clinical Medicine, laying a strong foundation in clinical sciences. Her commitment to women’s health and reproductive medicine led her to pursue a Ph.D. in Obstetrics and Gynecology at Peking University, one of China’s premier medical institutions.

đź©şPROFESSIONAL ENDEAVORS

Ms. Chen has consistently demonstrated excellence in both academic and clinical settings. As a Licensed Physician in China, she bridges research and clinical application, ensuring her work has tangible impact on patient care. Her academic training has been complemented by significant research experience, especially in the field of reproductive genetics.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON PREIMPLANTATION GENETIC TESTING(PGT)

Ms. Chen’s research primarily explores the genetic etiology of adverse pregnancy outcomes, with a special emphasis on Preimplantation Genetic Testing for Monogenic diseases (PGT-M). Her major contributions include:

  1. Investigation of genetic causes of recurrent fetal anomalies, especially those unexplained by traditional diagnostics.

  2. Application of PGT-M in hereditary tumor syndromes, even in cases without a known family history—enhancing the scope and sensitivity of reproductive genetic screening.

  3. Exploring key gene functions in blastocyst development and implantation, bridging the gap between molecular genetics and clinical reproductive outcomes.

🌍IMPACT AND INFLUENCE

Ms. Chen’s work has contributed to advancing precision reproductive medicine in China and beyond. Her research on using affected embryos or single sperm for linkage analysis in PGT-M has opened new avenues for patients with hereditary tumors lacking family history—setting new standards for ethical and practical approaches in assisted reproduction.

🏆ACCOLADES AND RECOGNITION

  • Outstanding Student Cadre, Peking University

  • National Second-Class Academic Scholarship

  • Outstanding Individual in Summer Social Practice, Peking University

These honors reflect her academic excellence, leadership qualities, and community engagement.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Ms. Chen is poised to become a leading figure in reproductive genetics, particularly in the ethical expansion and technical innovation of PGT-M. Her dedication to unraveling complex genetic causes of adverse pregnancy is expected to revolutionize the early detection and prevention of hereditary diseases.

🧬CONCLUSION

Ms. Xi Chen stands at the forefront of reproductive genetics research. With a rare combination of clinical experience, scientific rigor, and innovative thinking, she continues to shape the future of personalized reproductive healthcare. Her commitment to improving diagnostic and therapeutic outcomes for families affected by genetic disorders is both admirable and impactful.

📊🔬NOTABLE PUBLICATION:

Application of the PGT-M strategy using single sperm and/or affected embryos as probands for linkage analysis in males with hereditary tumor syndromes without family history

  • Authors: Chen X#, Wang Y, Guan S, Yan Z, Zhu X, Kuo Y, Wang N, Zhi X, Lian Y, Huang J, Liu P, Li R, Yan L, Qiao J
  • Journal: Journal of Human Genetics
  • Year: 2023 (Published August 18)

Functional profiling of stage-specific proteome and translational transition across human pre-implantation embryo development at a single-cell resolution

  • Dang Y#, Zhu L#, Yuan P#, Liu Q#, Guo Q, Chen X, Gao S, Liu X, Ji S, Yuan Y, Lian Y, Li R, Yan L*, Wong C*, Qiao J*
  • Journal: Cell Discovery
  • Year: 2023

Advances in studying human gametogenesis and embryonic development in China

  • Authors: Liu Q#, Chen X#, Qiao J
  • Journal: Biology of Reproduction
  • Year: 2022

Gang Liu | Stem Cell Therapy | Best Researcher Award

Posted on by Pencis

Prof. Dr. Gang Liu | Stem Cell Therapy | Best Researcher Award

University-Town Hospital of Chongqing Medical University | China

AUTHOR PROFILE

SCOPUS ID

🏥DR. GANG LIU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Liu Gang embarked on his medical journey with a strong commitment to excellence in clinical medicine and translational research. After completing his medical degree in China, he pursued postdoctoral training (2008–2010) at the Division of Pulmonary and Critical Care Medicine, Long Island Jewish Medical Center, affiliated with the Albert Einstein College of Medicine in New York, USA. This critical early exposure to international clinical and research environments laid a strong foundation for his future leadership in emergency and critical care medicine.

đź©şPROFESSIONAL ENDEAVORS

Dr. Liu currently serves as Chief Physician and Deputy Director at the Department of Emergency Medicine, University Town Hospital, affiliated with Chongqing Medical University. In parallel, he holds a vital administrative role as a Party Committee Member, contributing to strategic hospital governance.

Over the past two decades, Dr. Liu has risen through academic and clinical ranks, now holding titles such as Professor and Chief Physician in Critical Care Medicine, affirming his standing as a national leader in emergency and intensive care services.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON PEDIATRIC CRITICAL CARE MEDICINE

Though Dr. Liu is recognized primarily for his work in adult emergency medicine, his recent research interest has extended into Pediatric Critical Care Medicine, especially in areas intersecting with:

  • Pediatric Sepsis

  • Multi-organ Dysfunction Syndrome (MODS) in Children

  • Early detection and immune modulation in pediatric ICU patients

  • Neonatal emergency protocols during systemic infections

He has led cross-disciplinary initiatives to integrate pediatric-specific protocols into broader critical care workflows, optimizing early recognition and organ support strategies for critically ill pediatric patients in resource-variable settings.

🌍IMPACT AND INFLUENCE

Dr. Liu’s influence reaches national and regional health policy circles, particularly through his roles as:

  • Vice President, Hospital Safety Production Branch, National Association of Health Industry Management

  • Deputy Chair, Security and Protection Committee, Chongqing Hospital Association

Through these positions, he has helped shape emergency care infrastructure, establish hospital safety protocols, and train future critical care leaders, particularly in Western China—a focus of the “Western Region Healthcare Technical Backbone Talent Development Program” he was selected for in 2011.

🏆ACADEMIC CITES, ACCOLADES AND RECOGNITION

Dr. Liu has authored or co-authored numerous peer-reviewed articles, particularly in the domains of sepsis pathophysiology, organ injury, and critical care systems management. His academic work has been:

  • Cited over 1,000 times, reflecting robust clinical relevance and research translation.

  • Recognized in both Chinese national journals and international platforms, particularly for contributions to sepsis immunopathology and ICU systems optimization.

He was also selected for advanced ICU training at Peking University People’s Hospital, one of China’s leading tertiary institutions.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Liu is actively mentoring the next generation of emergency physicians and critical care researchers. He is involved in:

  • Designing pediatric emergency simulation training programs

  • Publishing ICU practice manuals that are being adopted in Chongqing province and beyond

  • Leading multi-center trials on pediatric sepsis resuscitation protocols

His long-term goal is to bridge the gap between adult and pediatric critical care, creating holistic emergency care ecosystems in resource-limited settings.

🧬CONCLUSION

Dr. Liu Gang, MD is a visionary leader in China’s critical and emergency medicine landscape, with a growing footprint in Pediatric Critical Care Medicine. His integrative approach, combining clinical excellence, hospital management, and research acumen, positions him as a catalyst for transformative healthcare solutions in both adult and pediatric critical care.

📊🔬NOTABLE PUBLICATION:

VNS facilitates the neurological function recovery after ischemia/reperfusion injury by regulating the A1/A2 polarization of astrocytes through the NMU-NMUR2 pathway

Authors: X. Jiang, Wendi Yang, Gang Liu, Changqing Li, Sheng Li

Journal: Neurochemistry International

Year: 2025

Xinli Shi | Tumor | Best Researcher Award

Posted on by Pencis

Ms. Xinli Shi | Tumor | Best Researcher Award

Shanxi University of Chinese Medicine | China

AUTHOR PROFILE

SCOPUS ID

ORCID ID

🏥MS. XINLI SHI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Ms. Xinli Shi, a Chinese national, began her academic journey with a B.Sc. in Biochemistry from the Department of Bioengineering at Hebei University of Science and Technology (1996–2001). She deepened her expertise in immunological mechanisms with an M.Sc. in Medical Immunology (2003–2007) from Hebei Medical University, followed by a Ph.D. in Immunology (2011–2014) from the West China College of Basic Medicine and Forensic Medicine, Sichuan University—one of China’s top-tier medical schools.

đź©şPROFESSIONAL ENDEAVORS

Prof. Shi’s academic career spans over two decades, reflecting progressive growth:

  • 2001–2013: She served at Hebei Medical University as a Teaching Assistant and then Lecturer, establishing foundational teaching experience.

  • 2013–2018: Appointed Associate Professor and Master’s Supervisor at the School of Basic Medicine, Hebei University of Chinese Medicine.

  • 2015–2017: Completed a Postdoctoral Fellowship at the Bethune International Peace Hospital, affiliated with the Third Military Medical University, focusing on advanced clinical research.

  • 2018–2023: Promoted to Professor and Doctoral Supervisor at Hebei University of Chinese Medicine.

  • 2023–Present: Serving as Professor and Doctoral/Master Supervisor at the Experimental Management Center, Shanxi University of Chinese Medicine.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR

Prof. Shi has made notable contributions in the field of tumor immunology, particularly within the tumor microenvironment, focusing on:

  • Autophagy

  • Drug Resistance

  • Restenosis

  • Inflammation-induced tumorigenesis

Her research explores how immune signaling and cellular stress responses shape tumor progression and therapeutic resistance, offering novel targets for immunomodulatory and chemotherapeutic interventions.

She has guided:

  • 3 Ph.D. students

  • 20+ M.D. students

  • Supervised postdoctoral fellows, actively fostering academic development and translational medicine research.

🌍IMPACT AND INFLUENCE

Prof. Shi’s work is highly regarded in both Western medicine and Traditional Chinese Medicine (TCM) circles. Her interdisciplinary approach integrates modern immunology with TCM principles, enabling translational applications in cancer and chronic disease therapy. She has been part of numerous provincial and national talent programs, contributing to science policy and medical education reform.

🏆RESEARCH GRANTS AND FUNDING

Prof. Shi has led 14 research projects, funded by prestigious national and provincial bodies. These include:

  • 2 National Natural Science Foundation of China (NSFC) grants (No. 81873112 & 82274315)

  • China Postdoctoral Science Foundation

  • Hebei Natural Science Foundation (multiple years)

  • Shanxi Science and Technology Department

  • Shanxi Provincial Administration of Traditional Chinese Medicine Innovation Team

🔹 Total grant portfolio spans over a decade, supporting basic, translational, and clinical research initiatives.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Prof. Shi’s career exemplifies academic excellence, clinical relevance, and mentorship. With growing involvement in Shanxi’s TCM innovation programs, she is positioned to pioneer integrative oncology in China—blending evidence-based traditional practices with cutting-edge immunotherapy research. Her future directions include:

  • Building innovation teams

  • Leading multi-center translational studies

  • Expanding doctoral and postdoctoral programs

  • Enhancing international collaborations in cancer research

🧬CONCLUSION

Prof. Xinli Shi stands at the confluence of biochemistry, medical immunology, and TCM oncology, with over 20 years of academic and clinical experience. Her dedication to tumor biology, immune modulation, and interdisciplinary research continues to shape the landscape of cancer therapeutics in China. As a mentor, scholar, and innovator, she contributes profoundly to the development of next-generation scientists and the advancement of personalized medicine.

📊🔬NOTABLE PUBLICATION:

RalB promotes lymph node metastasis in tongue squamous cell carcinoma

Authors: Y. Zhang, Yuman; Z. Liu, Zhihan; Y. Yang, Yanguang; L. Jia, Lifeng; X. Shi, Xinli
Journal: Genes and Genomics
Year: 2025

Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma

Authors: Y. Yang, Yanguang; S. Li, Shenghao; Q. Peng, Qing; Y. Zhang, Yuman; X. Shi, Xinli
Journal: Molecular Biology Reports
Year: 2024

Recent advances in graphitic carbon nitride-based heterojunction for biomedical applications

Authors: R. Jia, Ruilong; C. He, Cheng’en; S. Wang, Shanshan; G. Liao, Guangfu; X. Shi, Xinli
Citations: 3

Zhichen Xu | Radiation Oncology | Best Researcher Award

Posted on by Pencis

Zhichen Xu | Radiation Oncology | Best Researcher Award

First Hospital of Quanzhou | China

AUTHOR PROFILE

SCOPUS ID

🏥MR. ZHICHEN XU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Mr. Xu Zhichen, originally from Putian and a member of the Han ethnic group, embarked on his medical journey at Luzhou Medical College, where he earned his Bachelor’s degree in Clinical Neurology (2005–2010). Driven by a growing interest in cancer care, he pursued a Master’s degree in Radiation Oncology at Fujian Medical University (2010–2013). His postgraduate training, conducted at the Fujian Provincial Tumor Hospital, laid the foundation for his specialization in radiotherapy.

đź©şPROFESSIONAL ENDEAVORS

After completing his academic training, Mr. Xu underwent standardized residency training at Quanzhou First Hospital (2013.9–2014.9). Since September 2014, he has been an integral part of the hospital’s Radiotherapy Department, where he applies advanced radiotherapeutic techniques in clinical oncology. In 2024, he achieved the Vice Senior Certification in Radiotherapy, a testament to his professional growth and clinical mastery over the past decade.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON RADIATION ONCOLOGY

Mr. Xu specializes in Radiation Oncology, with a particular emphasis on esophageal cancer, focusing on enhancing therapeutic efficacy and patient outcomes. His clinical efforts are complemented by a strong commitment to research in radiotherapy optimization, side effect mitigation, and individualized treatment approaches.

🌍IMPACT AND INFLUENCE

A rising leader in regional cancer care, Mr. Xu is a core member of the Youth Committee of the Fujian Radiation Oncology Society. His selection for the “Hundred Talent Program” at Quanzhou First Hospital underlines his value as a future-forward clinician contributing to institutional development and innovation in cancer treatment.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Mr. Xu Zhichen aims to deepen his impact through work on precision radiotherapy, multidisciplinary cancer management, and the integration of AI and imaging technologies in clinical decision-making. He is committed to mentoring young oncologists and fostering collaborative research within and beyond Quanzhou.

🧬CONCLUSION

Mr. Xu Zhichen exemplifies the ideal blend of clinical expertise, research acumen, and leadership potential in the field of Radiation Oncology. With a focus on esophageal cancer, he continues to shape the future of radiotherapy in Fujian Province while contributing meaningfully to national and international cancer care standards.

 

📊🔬NOTABLE PUBLICATION:

A dynamic nomogram for predicting abdominal lymph node recurrence in patients with esophageal carcinoma

Authors: Xu Zhichen, Su Baoan, Lin Mingqiang, Xu Qinghua, Qu Mengke
Journal: Scientific Reports
Year: 2025

Dong Zhu | Organ-Defined Cancers | Best Researcher Award

Posted on by Pencis

Dong Zhu | Organ-Defined Cancers | Best Researcher Award

临沂大学 | China

AUTHOR PROFILE

SCOPUS ID

🏥MR. DONG ZHU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Born in May 1999 in Zaozhuang, Shandong Province, China, Mr. Zhu Dong displayed an early aptitude for analytical thinking and computing. He embarked on his academic journey at Linyi University, earning a Bachelor of Engineering in Computer Science and Technology (2020–2022). Recognized for his diligence and academic excellence, he was admitted into the university’s graduate program, where he is currently pursuing a Master of Engineering in Computer Technology (2022–2025).

đź©şPROFESSIONAL ENDEAVORS

While still a graduate student, Mr. Zhu has already made substantial strides in the field of medical image processing. He has co-developed advanced deep learning frameworks tailored to complex clinical imaging tasks, such as 3D liver segmentation and breast tumor analysis. His participation in collaborative and interdisciplinary projects reflects a forward-looking and adaptable research mindset.

🔬CONTRIBUTIONS AND RESEARCH FOCUS

Mr. Zhu’s primary research focus is on deep learning applications in medical image segmentation, with specific interests in:

  • 3D U-Net architectures
  • Attention mechanisms
  • Multi-scale feature fusion
  • Electrocardiogram (ECG) signal classification

🏆AWARDS AND HONOURS

  • National Scholarship, 2023–2024
  • First-Class Academic Scholarship, 2022–2023 & 2023–2024
  • Outstanding Communist Youth League Cadre, 2023–2024
  • Excellent Student Award, 2023–2024
  • Advanced Individual Award, 2023–2024

🌍IMPACT AND INFLUENCE

Though early in his career, Mr. Zhu’s models are contributing to more accurate, automated diagnosis systems in clinical imaging. His open-access publications and conference proceedings are cited in discussions around deep learning for medical applications, particularly in liver and breast imaging workflows. His interdisciplinary work is fostering stronger links between AI and clinical diagnostics.

🏆LEGACY AND FUTURE CONTRIBUTIONS

With a growing portfolio of first-author publications, Mr. Zhu is establishing himself as a rising researcher in AI-driven medical imaging. His focus on practical, clinically relevant problems positions him to contribute significantly to next-generation diagnostic technologies. In the coming years, he aims to expand his research to include multimodal imaging analysis, federated learning, and real-time diagnostic systems for point-of-care settings.

🧬CONCLUSION

Mr. Zhu Dong represents a new wave of interdisciplinary researchers who blend deep learning techniques with clinical needs. His trajectory reflects not only strong technical skills but also a deep commitment to improving healthcare through innovation. With continued support, mentorship, and exposure to global research networks, he is well-poised to lead breakthroughs in intelligent medical diagnostics.

 

📊🔬NOTABLE PUBLICATION:

3DMAU-Net: Liver Segmentation Network Based on 3D U-Net

Authors: Zhu, Dong; Ma, Tianyi; Yang, Mengzhu; Hu, Shunbo; Wang, Yongfang
Journal: Optoelectronics Letters
Year: 2025

Haixin Liang | Oncology Nursing | Best Researcher Award

Posted on by Pencis

Ms. Haixin Liang | Oncology Nursing | Best Researcher Award

Sichuan Cancer Hospital | China

AUTHOR PROFILE

ORCID ID

🎓 EARLY ACADEMIC PURSUITS

Born in April 1987 in China, Haixin Liang embarked on her journey in healthcare with a deep commitment to service and academic excellence. She earned her Master’s degree in Nursing, laying the foundation for a focused career in oncology nursing. Her early academic training fostered a keen interest in clinical innovation, evidence-based care, and nursing education.

🏆 PROFESSIONAL ENDEAVORS

Since July 2012, Liang has served at Sichuan Cancer Hospital, one of China’s leading institutions in cancer treatment and research. Currently holding the position of Nurse Supervisor and Oncology Advanced Practice Nurse, she plays a pivotal role in patient care management, nursing staff training, and clinical innovation. Liang’s responsibilities span clinical supervision, implementation of best nursing practices, and mentoring student nurses.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY NURSING

Haixin Liang’s professional contributions are deeply rooted in the nursing care of oncology patients, particularly focusing on:

  • Radiation-induced complications

  • Patient-centered safety practices

  • Clinical device innovations for cancer care

Her research often emphasizes the quality of life of nasopharyngeal carcinoma patients, symptom management, and infection control.

🌍 IMPACT AND INFLUENCE

Liang’s innovations and scholarly work have had a direct impact on clinical practice, particularly in:

  • Infection control through safe disposal of medical sharps

  • Improved nursing techniques in managing radiation-induced complications

  • Enhancing communication and understanding between caregivers and patients

Her educational leadership has influenced the next generation of oncology nurses, while her research is integrated into hospital protocols and academic curricula.

.

đź“– ACADEMIC CITATIONS AND RECOGNITION

While specific citation data is not provided here, her frequent first-author contributions in core Chinese nursing journals suggest substantial academic recognition and relevance in the field of clinical nursing innovation, especially among oncology nursing practitioners in China.

đź”®RESEARCH GRANTS AND FUNDING

Liang’s device innovations have led to two awarded patents, indicating support for clinical translation of nursing tools:

  • 🧪 Portable Sharps Disposal Container
    Patent Number: ZL 2014 20067555.3 – Issued: 2014.08.06

  • 🧪 Nasogastric Tube Injection Device
    Patent Number: ZL 2020 22568964.X – Issued: 2020.11.09

Her work is further supported through institutional awards and case competitions, signifying recognition and potential for funding in applied clinical research.

đź”® LEGACY AND FUTURE CONTRIBUTIONS

Haixin Liang’s legacy lies in:

  • Bridging practical nursing with innovation

  • Leading in radiotherapy nursing care

  • Cultivating student and staff excellence in oncology nursing

Her future contributions are expected to include:

  • Development of more patient-friendly clinical devices

  • Publishing guidelines for managing radiotherapy side effects

  • Expanding evidence-based nursing frameworks in oncology

🌍CONCLUSION 

Haixin Liang exemplifies a nurse leader who transcends bedside care through innovation, research, and mentorship. With a focused commitment to oncology nursing, her work continues to shape clinical practices and empower nursing professionals across China. Her profile is a testament to how clinical insight, scholarly pursuit, and technological innovation can converge in nursing for maximum patient impact.

 

📊🔬NOTABLE PUBLICATION:

Correlation between changes of taste or smell and self-reported symptoms in patients with nasopharyngeal carcinoma received radiotherapy and chemotherapy

Authors: Haixin Liang (First Author)

Journal: Guangdong Medical Journal

Year: 2018

 

Hongyu li | Breast Cancer | Best Researcher Award

Posted on by Pencis

Hongyu li | Breast Cancer | Best Researcher Award

Xinjiang medical university | China

AUTHOR PROFILE

SCOPUS

🎓EARLY ACADEMIC PURSUITS 

Assoc. Prof. Dr. Hongyu Li embarked on her academic journey at Xinjiang Medical University, where she earned her Doctor of Medicine degree and subsequently completed a Ph.D. in 2021. Her formative years were marked by rigorous academic training and an early interest in the oncology of breast diseases, which laid the foundation for her future specialization in breast cancer metastasis research.

👩‍🏢PROFESSIONAL ENDEAVORS 

Currently serving as an Associate Professor, Associate Chief Physician, and Doctor of Medicine at the Department of Breast Internal Medicine, Xinjiang Medical University Affiliated Tumor Hospital, Dr. Li brings over a decade of clinical expertise to the field. Her clinical focus is on the early detection, diagnosis, and management of breast cancer. She has been honored with prestigious awards including the “Tianchi Talent” Youth Doctor Award (2022), the Outstanding Postdoctoral Special Funding (2023), and was selected for the “789 Talent” Training Program (2024), cementing her reputation as a High-Level Talent and Outstanding Young Physician.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BREAST CANCER 

Dr. Li’s scientific inquiry is anchored in understanding the molecular mechanisms of breast cancer metastasis, with a specific focus on breast cancer brain metastasis (BCBM)—a critical and poorly understood manifestation associated with poor prognosis. Her translational research bridges clinical challenges and bench-side investigations, aiming to identify novel biomarkers and potential therapeutic targets for BCBM.

She adopts an integrative approach that translates clinical observations into mechanistic questions, enhancing the effectiveness of future treatments and diagnostic strategies for late-stage breast cancer.

📚IMPACT AND INFLUENCE 

Dr. Li’s work is contributing to shaping the clinical paradigms in breast cancer care within the Xinjiang region and beyond. Her research is improving understanding of metastatic processes, especially in underrepresented ethnic populations. She is also involved in institutional collaborations and has served in editorial capacities, reinforcing her influence in both academic and clinical oncology spheres.

💪LEGACY AND FUTURE CONTRIBUTIONS 

Looking forward, Dr. Li aims to establish a dedicated translational research unit focused on metastatic breast cancer, particularly BCBM. She is committed to mentoring young researchers and expanding interdisciplinary collaborations that bridge molecular oncology with precision medicine. Her ultimate goal is to redefine treatment algorithms and enhance survival outcomes for patients with advanced-stage breast cancer.

🌍CONCLUSION 

Assoc. Prof. Dr. Hongyu Li stands as a beacon of translational oncology, seamlessly integrating clinical care with cutting-edge research. Her relentless pursuit of knowledge, commitment to public health, and strategic focus on a critically unmet need in oncology make her a deserving nominee for the Best Researcher Award.

 

📊🔬NOTABLE PUBLICATION:

Title: GRB2 promotes brain metastasis in HER2-positive breast cancer by regulating the Ras/MAPK pathway

Authors: Hongyu Li, Yalin Zhang, Xiao Han, Bingyu Li, Dan Liu, Gang Sun

Journal: Scientific Reports (Nature Publishing Group)

Year: 2025

Jianhua Luo | Cellular Immunotherapy | Women Researcher Award

Posted on by Pencis

Jianhua Luo | Cellular Immunotherapy | Women Researcher Award

National Key Laboratory of Immunity & Inflammation, Institute of Immunology | China

AUTHOR PROFILE

Scopus

🎓 EARLY ACADEMIC PURSUITS

Ms. Jianhua Luo began her scientific journey at China Pharmaceutical University, earning a Bachelor’s degree in Food Quality and Safety (2012–2016). She pursued further specialization with a Master’s degree in Microbiology and Biochemical Pharmacy (2016–2019) from the same institution. With a growing interest in immunological mechanisms in disease treatment, she earned her Ph.D. in Medical Immunology (2020–2023) from the Second Military Medical University of the Chinese People’s Liberation Army — one of China’s most respected institutions in biomedical sciences.

🏆 PROFESSIONAL ENDEAVORS

Ms. Luo has engaged in collaborative, interdisciplinary research with emphasis on tumor immunotherapy, especially through CAR-NK cell engineering. Her work integrates molecular immunology, bioinformatics, and genetic engineering, with a strong translational focus. She has contributed extensively to both laboratory innovation and preclinical development of cellular immunotherapies for solid tumors.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CELLULAR IMMUNOTHERAPY

Ms. Luo has emerged as a key contributor in the cellular immunotherapy space, focusing on CAR-NK cells enhanced with synthetic cytokines (like Neoleukin-2/15) to improve anti-tumor efficacy in solid cancers. Her work on signal conversion platforms, which translate inhibitory signals into activation cues, represents a novel mechanism to bypass the immunosuppressive tumor microenvironment. She has co-developed autocrine IL-2Rβγ agonist-armored CAR-NK cells, now patented in China. Moreover, her interest extends to PANoptosis, immune cell metabolism in elderly populations, and immune responses to transplantation injuries.

🌍 IMPACT AND INFLUENCE

Her research, published in high-impact journals such as Signal Transduction and Targeted Therapy, Pharmacological Research, and the Journal of Translational Medicine, has influenced the next-generation design of adoptive cell therapies. She is a co-first or co-corresponding author in multiple publications that introduce disruptive approaches in the field. Additionally, her patent contributions and involvement in software development for AI-assisted cell therapy analysis have extended her impact into digital health and precision oncology.

đź“– ACADEMIC CITATIONS AND RECOGNITION

While a detailed citation count requires real-time database querying (e.g., Google Scholar or Scopus), her work appears in top-tier, peer-reviewed journals, suggesting she is accruing rapid academic citations, particularly around her publications on CAR-NK cells, tumor immune evasion, and chemo-immunotherapy synergy. Notably, her co-first author paper on Neoleukin-2/15-armored CAR-NK cells (2025) is expected to become a landmark citation in CAR-based immunotherapy research.

đź”® LEGACY AND FUTURE CONTRIBUTIONS

Ms. Luo’s patents, software copyrights, and published research point toward a legacy that bridges wet-lab biology and AI-powered immunotherapy solutions. Her tools for analyzing NK cell phenotypes and functions using machine learning and computer vision provide a strong base for future clinical translation and personalized immunotherapy. Her ongoing involvement in CAR-NK cell design, immune metabolism, and transplantation immunology positions her as a rising leader in precision immune-oncology.

🌍CONCLUSION 

Ms. Jianhua Luo represents a new generation of immunotherapy innovators—a multidisciplinary researcher who integrates molecular immunology, bioengineering, and computational tools to solve some of oncology’s most pressing challenges. With a robust publication record, recognized patents, software contributions, and involvement in national-level research programs, she is well-positioned to define the future landscape of cellular immunotherapy.

📊🔬NOTABLE PUBLICATION:

Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation

Journal: Signal Transduction and Targeted Therapy

Year: 2025

Citations: 1